Pulse Biosciences (PLSE) just cleared a key regulatory hurdle, with the FDA signing off on its Investigational Device Exemption for the nPulse Cardiac Catheter Ablation System in atrial fibrillation, ...

The US Food and Drug Administration (FDA) has granted approval for Abbott’s Volt PFA System, expanding treatment options for ...

The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...

Abbott has announced the company has received approval from the U.S. Food and Drug Administration (FDA) for its Volt PFA ...

Abbott will soon enter the competitive U.S. pulsed field ablation (PFA) market, having just received FDA approval for its ...

After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

Pulse Biosciences PLSE recently announced that the FDA has granted Investigational Device Exemption (“IDE”) approval to initiate its nPulse Cardiac Catheter Ablation System study for the treatment of ...

US FDA approves Abbott's Volt PFA System to treat patients with atrial fibrillation: Abbott Park, Illinois Wednesday, December 24, 2025, 12:00 Hrs [IST] Abbott, is a global health ...

Medtronic tops the list of the largest cardio device companies, with cardiovascular technology proving a major growth driver.

Abbott Laboratories is set to roll out its Volt PFA System in the U.S., following federal approval, and continue expanding ...

Abbott today announced the U.S. Food and Drug Administration (FDA) has approved the company's Volttm PFA System to treat patients battling atrial fibrillation (AFib). Abbott will soon begin commercial ...